Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Smoldering Multiple Myeloma 2 Prostatic Neoplasms 2 Monoclonal Gammopathy of Undetermined Significance 2 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Gastritis, Atrophic 1

Interventions

pembrolizumab 38 Bevacizumab 23 Cyclophosphamide 22 Standard of Care 18 Blood Specimen Collection 17 Carboplatin 16 Paclitaxel 15 Nivolumab 14 Gemcitabine 14 Pemetrexed 13 Exercise 13 Cisplatin 12 atezolizumab 11 Radiotherapy 11 Fluorouracil 11 Doxorubicin 11 Surveys and Questionnaires 9 Rituximab 9 Oxaliplatin 9 Magnetic Resonance Spectroscopy 9 Leucovorin 9 Cetuximab 9 Biopsy 9 130-nm albumin-bound paclitaxel 9 durvalumab 8 abemaciclib 8 Docetaxel 8 olaparib 7 Temozolomide 7 Prednisone 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Curcumin × 90 days × Clear all

NCT06626230 2026-05-18

Safety of Anal Curcumin

Emory University

Phase 1 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡